Camptothecin (CPT) directly binds to human heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) and inhibits the hnRNP A1/topoisomerase I interaction.

Camptothecin (CPT) is an anti-tumor natural product that forms a ternary complex with topoisomerase I (top I) and DNA (CPT-top I-DNA). In this study, we identified the direct interaction between CPT and human heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) using the T7 phage display technology. On an avidin-agarose bead pull down assay, hnRNP A1 protein was selectively pulled down in the presence of C20-biotinylated CPT derivative (CPT-20-B) both in vitro and in vivo. The interaction was also confirmed by an analysis on a quartz-crystal microbalance (QCM) device, yielding a K(D) value of 82.7 nM. A surface plasmon resonance (SPR) analysis revealed that CPT inhibits the binding of hnRNP A1 to top I (K(D): 260 nM) in a non-competitive manner. Moreover, an in vivo drug evaluation assay using Drosophila melanogaster showed that the knockout of the hnRNP A1 homolog Hrb87F gene showed high susceptibility against 5-50 μM of CPT as compared to a wild-type strain. Such susceptibility was specific for CPT and not observed after treatment with other cytotoxic drugs. Collectively, our data suggests that CPT directly binds to hnRNP A1 and non-competitively inhibits the hnRNP A1/top I interaction in vivo. The knockout strain loses the hnRNP A1 homolog as a both CPT-binding partner and naïve brakes of top I, which enhances the formation of the CPT-top I-DNA ternary complexes and subsequently sensitizes the growth inhibitory effect of CPT in D. melanogaster.

[1]  R. Hertzberg,et al.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.

[2]  M. Jafari,et al.  Can Drosophila melanogaster represent a model system for the detection of reproductive adverse drug reactions? , 2009, Drug discovery today.

[3]  K. Neugebauer,et al.  Cotranscriptional coupling of splicing factor recruitment and precursor messenger RNA splicing in mammalian cells , 2006, Nature Structural &Molecular Biology.

[4]  F. Zunino,et al.  Subcellular localization of the camptothecin analogues, topotecan and gimatecan. , 2004, Biochemical pharmacology.

[5]  I. Shalit,et al.  Quinolones as enhancers of camptothecin-induced cytotoxic and anti-topoisomerase I effects. , 2008, Biochemical pharmacology.

[6]  L. Liu,et al.  Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis. , 1997, Biochemical pharmacology.

[7]  M. Diener,et al.  Eicosanoid-mediated Cl− secretion induced by the antitumor drug, irinotecan (CPT-11), in the rat colon , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.

[8]  K. Morohashi,et al.  Screening of paclitaxel-binding molecules from a library of random peptides displayed on T7 phage particles using paclitaxel-photoimmobilized resin. , 2007, Bioconjugate chemistry.

[9]  R. W. Janes,et al.  Screening of a library of phage-displayed peptides identifies human bcl-2 as a taxol-binding protein. , 1999, Journal of molecular biology.

[10]  K. Sakaguchi,et al.  Use of phage display technology for the determination of the targets for small-molecule therapeutics , 2010, Expert opinion on drug discovery.

[11]  A. Dunker,et al.  Evolution and disorder. , 2011, Current opinion in structural biology.

[12]  K. Sakaguchi,et al.  Identification of a methotrexate-binding peptide from a T7 phage display screen using a QCM device. , 2008, Bioorganic & medicinal chemistry.

[13]  D. Johnson,et al.  The Drosophila Hrb87F gene encodes a new member of the A and B hnRNP protein group , 1991, Nucleic Acids Res..

[14]  S. Russell,et al.  Drosophila melanogaster as a model system for drug discovery and pathway screening. , 2002, Current opinion in pharmacology.

[15]  D. Scudiero,et al.  Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. , 2002, Cancer research.

[16]  C. Nichols,et al.  Human Disease Models in Drosophila melanogaster and the Role of the Fly in Therapeutic Drug Discovery , 2011, Pharmacological Reviews.

[17]  M. Christman,et al.  The Topoisomerase-related Function Gene TRF4 Affects Cellular Sensitivity to the Antitumor Agent Camptothecin* , 1999, The Journal of Biological Chemistry.

[18]  K. Sakaguchi,et al.  Identification of C10 biotinylated camptothecin (CPT-10-B) binding peptides using T7 phage display screen on a QCM device. , 2007, Bioorganic & medicinal chemistry.

[19]  M. Hagiwara,et al.  Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA , 2007, Nature Chemical Biology.

[20]  Yoichi Takakusagi,et al.  Camptothecin binds to a synthetic peptide identified by a T7 phage display screen. , 2005, Bioorganic & medicinal chemistry letters.

[21]  A. Girstun,et al.  SF2/ASF protein binds to the cap region of human topoisomerase I through two RRM domains. , 2005, Biochemical and biophysical research communications.

[22]  G. Schwartz,et al.  Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells. , 2002, Cancer research.

[23]  Ethan Bier,et al.  Using Drosophila melanogaster to uncover human disease gene function and potential drug target proteins , 2002, Expert opinion on therapeutic targets.

[24]  L. Makowski,et al.  Identification of small molecule binding sites within proteins using phage display technology. , 2001, Combinatorial chemistry & high throughput screening.

[25]  A. Dunker,et al.  Understanding protein non-folding. , 2010, Biochimica et biophysica acta.

[26]  A. Girstun,et al.  SF2/ASF protein inhibits camptothecin-induced DNA cleavage by human topoisomerase I. , 2002, European journal of biochemistry.

[27]  K. Sakaguchi,et al.  Identification of trimannoside-recognizing peptide sequences from a T7 phage display screen using a QCM device. , 2009, Bioorganic & medicinal chemistry.

[28]  M. Murawska,et al.  RRM proteins interacting with the cap region of topoisomerase I. , 2007, Journal of molecular biology.

[29]  L. Liu,et al.  Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. , 1988, Cancer research.

[30]  P. Berg,et al.  Renaturation of complementary DNA strands mediated by purified mammalian heterogeneous nuclear ribonucleoprotein A1 protein: implications for a mechanism for rapid molecular assembly. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[31]  A. McPhail,et al.  Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2 , 1966 .

[32]  K. Morohashi,et al.  Synthesis of a biotinylated camptothecin derivative and determination of the binding sequence by T7 phage display technology. , 2005, Bioorganic & medicinal chemistry letters.

[33]  X. F. Dong,et al.  Heterogeneous nuclear ribonucleoprotein A1 catalyzes RNA.RNA annealing. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Markovits,et al.  Protein arginine (N)‐methyl transferase 7 (PRMT7) as a potential target for the sensitization of tumor cells to camptothecins , 2008, FEBS letters.

[35]  S. Metallo,et al.  Intrinsically disordered proteins are potential drug targets. , 2010, Current opinion in chemical biology.

[36]  A. Ikari,et al.  Thromboxane A2, released by the anti‐ tumour drug irinotecan, is a novel stimulator of Cl− secretion in isolated rat colon , 1997, The Journal of physiology.

[37]  K. Morohashi,et al.  A Screening of a Library of T7 Phage-Displayed Peptide Identifies E2F-4 as an Etoposide-Binding Protein , 2011, Molecules.

[38]  K. Sakaguchi,et al.  A sulfoglycolipid beta-sulfoquinovosyldiacylglycerol (betaSQDG) binds to Met1-Arg95 region of murine DNA polymerase lambda (Mmpol lambda) and inhibits its nuclear transit. , 2010, Protein engineering, design & selection : PEDS.

[39]  G. Lazzeri,et al.  Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan , 2001, British journal of pharmacology.

[40]  Taro Nakamura,et al.  NBRP databases: databases of biological resources in Japan , 2009, Nucleic Acids Res..